<div id="readability-page-1"><p>TELA Bio (NASDAQ:TELA - Get Free Report) is expected to issue its  Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $18.5970 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.</p><p>TELA Bio (NASDAQ:TELA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $21.04 million. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>TELA Bio Stock Performance</h2><p>NASDAQ TELA traded up $0.10 during trading on Tuesday, hitting $1.19. The company's stock had a trading volume of 332,411 shares, compared to its average volume of 196,760. The firm has a market cap of $53.24 million, a P/E ratio of -1.43 and a beta of 1.30. TELA Bio has a 52 week low of $0.50 and a 52 week high of $2.20. The company has a quick ratio of 3.59, a current ratio of 4.20 and a debt-to-equity ratio of 8.82. The firm has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.98. </p><h2>Analyst Upgrades and Downgrades</h2><p>TELA has been the subject of a number of recent analyst reports. Piper Sandler dropped their price target on TELA Bio from $1.25 to $1.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, March 25th. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of TELA Bio in a research note on Tuesday, April 21st. Canaccord Genuity Group reduced their price target on shares of TELA Bio from $4.00 to $2.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, March 25th. Citizens Jmp lowered their price objective on shares of TELA Bio from $5.00 to $3.00 and set a &#34;market outperform&#34; rating for the company in a research report on Friday, March 27th. Finally, Lake Street Capital decreased their target price on TELA Bio from $3.00 to $2.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, March 25th. Three equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $2.20.</p><p><b>View Our Latest Analysis on TELA</b></p><h2>Institutional Trading of TELA Bio</h2><p>A number of large investors have recently added to or reduced their stakes in TELA. Citadel Advisors LLC lifted its position in  TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company's stock worth $53,000 after acquiring an additional 21,781 shares during the last quarter.  XTX Topco Ltd acquired a new stake in  TELA Bio during the 4th quarter worth approximately $48,000.  Renaissance Technologies LLC boosted its stake in  TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company's stock valued at $152,000 after purchasing an additional 64,800 shares during the period.  Finally, Susquehanna International Group LLP grew its holdings in  TELA Bio by 551.2% in the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company's stock valued at $128,000 after buying an additional 72,594 shares in the last quarter. Institutional investors and hedge funds own  94.35% of the company's stock. </p><h2>TELA Bio Company Profile</h2> (Get Free Report)<p>TELA Bio, Inc <span>NASDAQ: TELA<span></span></span> is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body's natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.  </p><p>The company's product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than TELA Bio</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in TELA Bio Right Now?</h2><p>Before you consider TELA Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.</p><p>While TELA Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TELA

<p>TELA Bio (NASDAQ: TELA) is set to release its Q1 2026 earnings on May 12, with analysts predicting a loss of $0.14 per share and revenue of $18.6 million. The company previously reported a loss of $0.16 per share for Q1 2025, exceeding estimates. TELA's stock is currently trading at $1.19, with a market cap of $53.24 million. Recent analyst ratings show a mix of buy, hold, and sell recommendations, with an average target price of $2.20. Institutional investors hold 94.35% of TELA's shares, indicating strong interest in the company.</p>

TELA Bio (TELA) Projected to Post Earnings on Tuesday